

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.ispito.gov

APPLIC	ATION NO.	FILING D	DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/	825,293	04/04/2	2001	Mike Farwick	P 280108 000561 BT	4063
909	7	590	01/18/2002			·
	PILLSBURY WINTHROP LLP				EXAMINER	
1600 TYSONS BOULEVARD MCLEAN, VA 22102		RD		FRONDA, CH	FRONDA, CHRISTIAN L	
					ART UNIT	PAPER NUMBER
					1652	11
					DATE MAILED: 01/18/2002	1

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. 09/825,293

Examiner

Applicant(s)

Christian L. Fr nda

Art Unit 1652

Farwick et al.



	The MAILING DATE of this communication appears	n the cover she t with the corres					
A SHO	for Reply ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE MONTH	I(S) FROM				
- Exten aft	esions of time may be available under the provisions of 37 C ter SIX (6) MONTHS from the mailing date of this communic period for reply specified above is less than thirty (30) days	cation.					
be - If NO	considered timely. period for reply is specified above, the maximum statutory mmunication.		·				
- Failur - Any r	rimunication. The to reply within the set or extended period for reply will, by eply received by the Office later than three months after the rned patent term adjustment. See 37 CFR 1.704(b).	y statute, cause the application to bec e mailing date of this communication,	ome ABANDONED (35 U.S.C. § 133). even if timely filed, may reduce any				
Status							
	Responsive to communication(s) filed on		•				
_		etion is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.						
	tion of Claims						
4) 💢	Claim(s) <u>1-19</u>	is/are	pending in the application.				
4	a) Of the above, claim(s)	is/ar	e withdrawn from consideration.				
5) 🗆	Claim(s)		is/are allowed.				
6) 🗆	Claim(s)		is/are rejected.				
7) 🗆	Claim(s)		is/are objected to.				
8) 💢	Claims <u>1-19</u>	are subject to restric	ction and/or election requirement.				
Applica	tion Papers						
9) 🗆	The specification is objected to by the Examiner.						
	The drawing(s) filed on is/are	•					
11)	The proposed drawing correction filed on	is: a)□ approved	b) disapproved.				
12) 🗌	The oath or declaration is objected to by the Exam	iner.					
Priority	under 35 U.S.C. § 119						
	Acknowledgement is made of a claim for foreign p	priority under 35 U.S.C. § 119(a)	-(d).				
a) L_	All b)☐ Some* c)☐ None of:						
	1. Certified copies of the priority documents have						
	2. ☐ Certified copies of the priority documents have						
	 Copies of the certified copies of the priority days application from the International Bures the attached detailed Office action for a list of the 	eau (PCT Rule 17.2(a)).	this National Stage				
14)	Acknowledgement is made of a claim for domestic		(e).				
Attachme	ent(s)						
15) 🗌 No	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper	No(s)				
	otice of Dreftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application	(PTO-152)				
17) 📙 Inf	formation Disclosure Statement(s) (PTO-1449) Peper No(s)	20) Other:					

Art Unit: 1652

DETAILED ACTION

Page 2

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-7, 9, and 19, drawn to an isolated polynucleotide, a vector, and a coryneform bacteria comprising said polynucleotide, classified in class 435, subclass 252.32.
 - II. Claim 8, drawn to a coryneform bacteria in which the mikE17 gene is attenuated, classified in class 435, subclass 252.1.
 - III. Claim 10 and 18, drawn to a process for the fermentative preparation of lysine comprising fermenting a coryneform bacteria which has the mikE17 gene attenuated, classified in class 435, subclass 115.
 - IV. Claims 10, 11, and 18, drawn to a process for the fermentative preparation of lysine comprising fermenting a coryneform bacteria which has the mikE17 gene attenuated and genes of the biosynthesis pathway of the amino acid are additionally enhanced, classified in class 435, subclass 115.
 - V. Claims 10, 12, and 18, drawn to a process for the fermentative preparation of lysine comprising fermenting a coryneform bacteria which has the mikE17 gene attenuated and the metabolic pathways which reduce the formation of the amino acid are at least partly eliminated, classified in class 435, subclass 115.
 - VI. Claims 10, 13, and 18, drawn to a process for the fermentative preparation of lysine comprising fermenting a coryneform bacteria which has the mikE17 gene eliminated, classified in class 435, subclass 115.
 - VII. Claims 10, 14, and 18, drawn to a process for the fermentative preparation of lysine comprising fermenting a coryneform bacteria wherein the regulatory properties of the mikE17 protein are reduced, classified in class 435, subclass 115.
 - VIII. Claims 10, 15, and 18, drawn to a process for the fermentative preparation of lysine comprising fermenting a coryneform bacteria which has the mikE17 gene attenuated and one or more genes are enhanced selected from the group consisting

Art Unit: 1652

of the dapA, gap, tpi, pgk, zwf, pyc, mqo, lysC, lysE, hom, ilvA, ilvBN, ilvD, and zwal gene, classified in class 435, subclass 115.

- IX. Claims 10, 16, and 18, drawn to a process for the fermentative preparation of lysine comprising fermenting a coryneform bacteria which has the mikE17 gene attenuated and one or more genes are attenuated selected from the group consisting of the pck, pgi, poxB, and zwa2 gene, classified in class 435, subclass 115.
- X Claim 19, drawn to a process for discovering RNA, cDNA and DNA using hybridization probes, classified in class 435, subclass 6.
- 2. The inventions are distinct, each from the other because of the following reasons:
 Inventions of Groups I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). Each of the products of Groups I and II are independent chemical entities and require different literature searches.

Inventions of Groups III-X are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). Each of the processes of Groups III-X are distinct both physically and functionally and require different process steps, reagents, and parameters.

Inventions I and X are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product such as using the polynucleotide in a recombinant process for the production of the MikE17 protein.

Inventions II and (III-IX) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product such as using coryneform bacteria in a recombinant process for the production of the attenuated MikE17 protein.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for

Page 4

Art Unit: 1652

examination purposes as indicated is proper.

3. The claims are generic to a plurality of disclosed patentably distinct species. Applicants are required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

For Group VIII, the species are each of the dapA, gap, tpi, pgk, zwf, pyc, mqo, lysC, lysE, hom, ilvA, ilvBN, ilvD, and zwal genes. If this group is elected, then Applicants must elect only one gene for examination.

For Group IX, the species are each of the pck, pgi, poxB, and zwa2 genes. If this group is elected, then Applicants must elect only one gene for examination.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L. Fronda whose telephone number is (703)305-1252. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703)308-3804. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703)308-0196.

A response to this Office Action may be faxed directly to the Examiner whose Fax Number is (703)746-5036 in order to expedite prosecution.

CLF

PONNATHAPU ACHUTAMURTHY SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600